Compare
Perrigo Co PLC vs Organon & Co. vs Phibro Animal Health Corp vs Regeneron Pharmaceuticals, Inc.
| Latest fiscal year | Perrigo Co PLC PRGO | Organon & Co. OGN | Phibro Animal Health Corp PAHC | Regeneron Pharmaceuticals, Inc. REGN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | $4.25B | $6.22B | $1.52B | $14.34B |
| Revenue growth (YoY) | -2.8% | -2.9% | +17.1% | +1.0% |
| Gross margin | 35.1% | 53.3% | 33.8% | n/a |
| Operating margin | -26.4% | n/a | 12.8% | 24.9% |
| Net margin | -33.5% | 3.0% | 6.6% | 31.4% |
| Net income | -$1.43B | $187.00M | $99.72M | $4.50B |
| EPS (Diluted) | -$10.29 | $0.72 | $2.43 | $41.48 |
| Operating cash flow | $238.50M | $700.00M | $68.95M | $4.98B |
| Free cash flow | $145.10M | $538.00M | $9.87M | $4.08B |
| Cash & equivalents | n/a | $574.00M | $61.42M | $3.12B |
| Total assets | $8.54B | $12.87B | $1.50B | $40.56B |
| Total liabilities | $5.60B | $12.12B | $1.12B | $9.30B |
| Shareholders' equity | $2.94B | $752.00M | $385.48M | $31.26B |
| Return on year-end equity | -48.6% | 24.9% | 25.9% | 14.4% |
| Shares outstanding | 137.60M | 260.32M | n/a | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Perrigo Co PLC | Organon & Co. | Phibro Animal Health Corp | Regeneron Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $4.25B Ended 2025-12-31 | $6.22B Ended 2025-12-31 | $1.52B Ended 2026-06-30 | $14.34B Ended 2025-12-31 |
| 1 year earlier | $4.37B Ended 2024-12-31 | $6.40B Ended 2024-12-31 | $1.30B Ended 2025-06-30 | $14.20B Ended 2024-12-31 |
| 2 years earlier | $4.66B Ended 2023-12-31 | $6.26B Ended 2023-12-31 | $1.02B Ended 2024-06-30 | $13.12B Ended 2023-12-31 |
| 3 years earlier | $4.45B Ended 2022-12-31 | $6.17B Ended 2022-12-31 | $977.89M Ended 2023-06-30 | $12.17B Ended 2022-12-31 |
| 4 years earlier | $4.14B Ended 2021-12-31 | $6.30B Ended 2021-12-31 | $942.26M Ended 2022-06-30 | $16.07B Ended 2021-12-31 |